Tech-bio company Vinotech Co., Ltd. received evaluations that its premium red ginseng product “Daehansammac,” unveiled at “CES 2026” in Las Vegas, United States, demonstrated differentiation in the way products and technologies are applied, compared with those of global bio and healthcare companies.

At “CES 2026,” bio and healthcare companies from North America, Europe, and Asia participated and showcased products based on fermented ingredients, functional foods, personalized nutrition solutions, and microbiome-related products. Breaking with the convention of introducing products mainly by raw material characteristics or functional concepts, Vinotech drew attention by explaining its products around a technology application framework that proceeds from molecular conversion → absorption structure design → verification of functional expression.

According to Vinotech, “Daehansammac” is a concentrated red ginseng product that applies a fermentation process based on its proprietary strain BNT L-408, which converts high-molecular ginsenosides into low-molecular ginsenosides with higher bioavailability. The strain is protected by an international patent, and through its use, the contents of key ginsenosides such as Rg3, Rg5, and Rk1 were found to increase significantly compared with conventional red ginseng. This was described as a molecular-level approach distinct from simple concentration or blending methods.

In terms of finished product specifications, each stick of “Daehansammac” contains approximately 100 mg of total ginsenosides, including about 70 mg of Rg3. However, at the CES site, buyers’ interest focused more on verification results for in vivo absorption rates than on content levels. Vinotech explained that in animal studies, Daehansammac recorded approximately 18 times higher Rg3 absorption and about 17 times higher Rg5 absorption compared with standard red ginseng concentrate.

In addition, joint research with the Korea Research Institute of Chemical Technology presented evaluation results related to metabolic functions, including blood glucose reduction, improvement in insulin resistance, and liver function indicators. On this basis, “Daehansammac” was introduced not as a raw material-centered health supplement, but as a technology-based product that can explain the structure of functional expression.

Overseas buyers who took part in on-site consultations cited as key review factors: △the explanatory framework for the absorption mechanism △technology-centered positioning suitable for the premium healthcare and functional food markets △a data-based product explanation approach required in the North American and European markets.

In the domestic market, “Daehansammac” is sold at around 150 “Claunge” stores nationwide through the distribution networks operated by Convinos Co., Ltd. and Familounge Co., Ltd.

Vinotech CEO Kim Yu-mi stated, “What global buyers focused on most at CES was not the fermentation process or the raw material itself, but the structure in which technology completes the efficacy,” and added, “Through this CES, Vinotech has presented the pinnacle of platformization technology for nano-bio materials and mass production and commercialization technologies, and has clearly declared its strategic direction as a Tech-Bio company.”

Popular News